You have 9 free searches left this month | for more free features.

carboplatin

Showing 26 - 50 of 1,824

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Advanced Cancer Trial in Houston (Temsirolimus, Bevacizumab, Paclitaxel)

Active, not recruiting
  • Advanced Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Oct 11, 2022

Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)

Completed
  • Breast Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 20, 2022

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Breast Cancer Trial in United States (carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat)

Active, not recruiting
  • Breast Cancer
  • carboplatin
  • +3 more
  • Birmingham, Alabama
  • +4 more
Feb 1, 2023

NSCLC Trial in Boston, New York (MPDL3280A, Carboplatin, Nab-paclitaxel)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Boston, Massachusetts
  • +1 more
Oct 12, 2022

Adenocarcinoma of Lung, NSCLC Trial in Rolling Meadows (LP-300, Pemetrexed, Carboplatin)

Not yet recruiting
  • Adenocarcinoma of Lung
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Jul 8, 2022

Non Small Cell Lung Cancer Trial in Scottsdale, Rochester (Proton Beam Therapy, Carboplatin, Paclitaxel)

Recruiting
  • Non Small Cell Lung Cancer
  • Proton Beam Therapy
  • +2 more
  • Scottsdale, Arizona
  • +1 more
Nov 9, 2022

Carcinoma, Non-Small-Cell Lung Trial in Beijing (HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar,

Recruiting
  • Carcinoma
  • Non-Small-Cell Lung
  • HLX10, an engineered anti-PD-1 antibody
  • +3 more
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences (CAMS)
Apr 29, 2022

Prostate Cancer Aggressiveness, Prostate Carcinoma Trial in Houston (Cabazitaxel, Carboplatin, Prednisone 5Mg)

Active, not recruiting
  • Prostate Cancer Aggressiveness
  • Prostate Carcinoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 5, 2022

Head Neck Cancer, Head and Neck Tumors, Squamous Cell Carcinoma of Head and Neck Trial in Chicago (Xevinapant, Carboplatin,

Not yet recruiting
  • Head and Neck Cancer
  • +2 more
  • Chicago, Illinois
    University of Chicago Medicine Comprehensive Cancer Center
Oct 25, 2023

Extensive-stage Small-cell Lung Cancer Trial in China (serplulimab, Cisplatin, Carboplatin)

Not yet recruiting
  • Extensive-stage Small-cell Lung Cancer
  • Shantou, Guangdong, China
  • +6 more
Mar 1, 2023

Ovarian Cancer, Chemotherapeutic Toxicity Trial in Evanston (Fasting Mimicking Diet (Xentigen by L'Nutra), Carboplatin,

Not yet recruiting
  • Ovarian Cancer
  • Chemotherapeutic Toxicity
  • Fasting Mimicking Diet (Xentigen by L'Nutra)
  • +3 more
  • Evanston, Illinois
    NorthShore University HealthSystem
Jun 25, 2023

Large Cell Neuroendocrine Carcinoma of the Lung Trial in Athens (Atezolizumab, Carboplatin, Etoposide)

Completed
  • Large Cell Neuroendocrine Carcinoma of the Lung
  • Athens, Greece
  • +1 more
Sep 16, 2023

Gynecologic Malignancies Trial in Cleveland (Paclitaxel, Carboplatin)

Terminated
  • Gynecologic Malignancies
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
Jun 29, 2022

Lung Cancer Trial in Houston (AMG 510, Cisplatin, Carboplatin)

Recruiting
  • Lung Cancer
  • AMG 510
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 10, 2022

NSCLC, Squamous Cell Carcinoma Trial in Wuhan (Nab-paclitaxel, Carboplatin, Thoracic radiation therapy)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Squamous Cell Carcinoma
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Apr 26, 2022

Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative Trial in United States (Atezolizumab, Carboplatin,

Active, not recruiting
  • Triple Negative Breast Cancer
  • +3 more
  • Washington, District of Columbia
  • +5 more
Dec 1, 2022

Untreated Advanced or Recurrent Thymic Carcinomas Trial in Chuo (MK-3475, Lenvatinib, Carboplatin)

Not yet recruiting
  • Untreated Advanced or Recurrent Thymic Carcinomas
  • Chuo, Tokyo, Japan
    National Cancer Center Hospital
Apr 16, 2023

Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Brain Metastases
  • Guangzhou, Guangzhou, China
    Li-Kun Chen
Nov 13, 2022

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)

Not yet recruiting
  • High Grade Ovarian Cancer
  • +2 more
  • Mirvetuximab soravtansine
  • Carboplatin
  • (no location specified)
Jul 11, 2022

Breast Tumor Trial in Shanghai (Decitabine, Carboplatin)

Terminated
  • Breast Neoplasm
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Mar 28, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in New Brunswick,

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Carboplatin
  • +2 more
  • New Brunswick, New Jersey
  • +2 more
Jun 28, 2022

Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid

Active, not recruiting
  • Acute Myeloid Leukemia
  • +9 more
  • Carboplatin
  • +3 more
  • Los Angeles, California
  • +5 more
Jan 27, 2023

Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer Trial (Carboplatin)

Not yet recruiting
  • Ovarian Cancer
  • +6 more
  • Carboplatin
  • (no location specified)
Oct 27, 2022

Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)

Completed
  • Non-Hodgkin's Lymphoma
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022